Novo Nordisk ($NVO) has some new data in hand that could help a safety advantage make its way onto the label of new drug Tresiba--and win it points against heavyweight rival Sanofi ($SNY). In a recent study, the med hit its primary endpoint, cutting the number of hypoglycemic events by 30% compared with the French drugmaker's Lantus. Tresiba's rate of hypoglycemia tallied 186 events per 100 patient years, compared with 265 on Lantus. And as for hypoglycemia episodes at night, the study's secondary endpoint, Tresiba slashed them by 42%. More from FiercePharmaMarketing

> Pfizer's Lyrica and Neurontin--meds that are often recommended as safer alternatives to opioid pain therapies--could face new U.K. restrictions thanks to increasing reports that they're being abused. More